Drug Type Targeted protein degraders |
Synonyms CT-09 |
Target |
Action inhibitors |
Mechanism RING E3 ligase inhibitors(RING-type E3 ubiquitin transferase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Autoimmune Diseases | Preclinical | Poland | 01 Sep 2023 | |
| Neoplasms | Preclinical | Poland | 01 Sep 2023 |





